a b s t r a c t GPR39, a G-protein-coupled receptor activated by zinc, reportedly activates multiple intracellular signaling pathways via Gs, Gq, G12/13, and b-arrestin, but little is known about downregulation of the receptor upon its activation. To our knowledge, this is the first report on the mechanism of feedback regulation of GPR39 function determined in GPR39-expressing HEK293 cells (HEK293-GPR39) as a model cell system. In HEK293-GPR39 cells, GPR39-C3, which is a positive allosteric modulator, activated cAMP production (downstream of Gs), IP1 accumulation (downstream of Gq), SRF-RE-dependent transcription (downstream of G12/13), and b-arrestin recruitment. GPR39-C3 induced dose-and time-dependent loss of response in cAMP production by second challenge of the compound. This functional desensitization was blocked by the Rho kinase (ROCK) inhibitor, Y-27632, but not by Gq or Gs-pathway inhibitors or inhibition of b-arrestin recruitment. In the receptor localization assay, GPR39-C3 induced internalization of GFP-tagged GPR39. This internalization was also inhibited by Y-27632, which suggested that ROCK activation is critical for internalization and desensitization of GPR39. A novel biased GPR39 positive allosteric modulator, 5-[2-[(2,4-dichlorophenyl)methoxy]phenyl]-2,2-dimethyl-1,3,5,6-tetrahydrobenzo[a]phenan thridin-4-one (GSB-118), which activated cAMP responses and b-arrestin recruitment but showed no effect on SRF-RE-dependent transcription, did not induce desensitization. These results revealed a unique mechanism of desensitization of GPR39.
Introduction
GPR39 is a G-protein-coupled receptor (GPCR) and a member of the ghrelin/neurotensin peptide receptor subfamily. Although the known ligands of this family are all peptides, GPR39 has been reported to be activated by Zn 2+ [1, 2] and to transduce intracellular signals via Gs, Gq, and G12/13 [2] [3] [4] . GPR39 has been shown to be widely expressed in several tissues, such as the pancreas, gastrointestinal tract, liver, kidney, and brain [5, 6] , and to be involved in a range of physiological function, including insulin secretion, gastric emptying, and cell protection [7] [8] [9] [10] . Several studies, including receptor knockout studies, have suggested that GPR39 is a potential target for several diseases, including type 2 diabetes and depression [7, [10] [11] [12] . Recently, some small molecules were reported to be GPR39 agonists [13] [14] [15] [16] . Among these, GPR39-C3 was reported to allosterically activate the effect of zinc in Gq, Gs, and b-arrestin pathways [16] and induce acute GLP-1 levels in mice [15] . It has been widely recognized that GPCRs may lead to receptor desensitization via activation of their function that terminates excess signal transduction into cells [17, 18] . This phenomenon is physiologically important to maintaining cellular homeostasis. This receptor regulatory process is controlled in different ways according to the receptor. The most well-known mechanism is internalization of the receptor induced by phosphorylation of the receptor by GPCR kinases (GRKs) followed by binding of b-arrestins to the receptor [17] [18] [19] . Internalized receptors are degraded in lysosomes (downregulation) or recycled to cell membranes. Although phosphorylation of the receptor by GRKs is thought to be a main trigger for internalization, regulation of the internalization of some receptors varies. For example, phosphorylated extracellular signal-regulated kinase (ERK) mediated by Gq-pathway activation reportedly is important for GLP-1R internalization [20, 21] . ERK has also been reported to have an important role in the internalization of GPCRs, such as 5-HT2A receptors and delta-opioid receptors [22, 23] . Additionally, some studies have shown that other kinases downstream of GPCRs are also involved in the internalization of GPCRs; protein kinase A (PKA) phosphorylates GRK2 and enhances its translocation to the membrane, resulting in enhancement of b2 adrenergic receptor (b2AR) phosphorylation and desensitization [24] . Protein kinase C (PKC) is also involved in the regulatory process of several GPCRs by modifying the GRK2 activity or ubiquitination of b-arrestin [25] [26] [27] . PKA and PKC can also mediate the uncoupling of receptors from heterotrimeric G proteins or internalization in some receptors leading to desensitization [28] [29] [30] .
Recently, the concept of ''biased agonism," also known as ''functional selectivity," a phenomenon in which a given ligand preferentially activates one (or some) of the intracellular signals, is one of the most active areas in GPCR research because biased ligands may offer improved therapeutic profiles [31] [32] [33] . Several studies have shown that biased ligands regulate receptor desensitization differently from that of ''balanced" ligands [34, 35] . For example, CCL19, an endogenous ligand for the chemokine receptor CCR7, induces Ca 2+ flux, receptor phosphorylation, arrestin recruitment, and desensitization, whereas another ligand, CCL21, induces Ca 2+ flux but not receptor phosphorylation, arrestin recruitment, and receptor desensitization [34] . Thus, desensitization of GPCRs is complexly regulated by multiple mechanisms depending on the receptor and ligand. Although Zn 2+ has been reported to induce functional desensitization in Ca 2+ responses in human keratinocyte HaCaT cells, which suggests desensitization of GPR39 [36] , the detailed desensitization properties induced by GPR39 activation remain unclear. In this study, we investigated the functional desensitization and internalization of GPR39 in HEK293 cells and revealed a unique mechanism of desensitization regulated by the G12/13/Rho kinase (ROCK) pathway. In accordance with this finding, a novel signal-biased positive allosteric modulator (PAM) that showed no effect on the G12/13 pathway but potentiated the Gs-pathway, failed to induce desensitization of GPR39.
Materials and Methods

Chemicals and drugs
GPR39-C3 and Cmpd101 hydrochloride were synthesized by Takeda Pharmaceutical Company. 5-[2-[(2,4-dichlorophenyl)meth oxy]phenyl]-2,2-dimethyl-1,3,5,6-tetrahydrobenzo[a]phenanthri din-4-one (GSB-118) was obtained from Intelbioscan Ltd. (Moscow, Russia). HEPES, Dulbecco's modified Eagle's medium (DMEM), McCoy's 5A medium, Opti-MEM, penicillin/streptomycin, and Hanks's balanced buffered saline (HBSS) were obtained from Life Technologies (Carlsbad, CA). Fetal bovine serum (FBS) was purchased from AusGeneX (Brisbane, Australia). PKI (14) (15) (16) (17) (18) (19) (20) (21) (22) amide (myristoylated) (PKI) was purchased from Enzo Life Sciences (Farmingdale, NY). Other materials were from Wako Pure Chemical Industries (Osaka, Japan) unless otherwise noted.
Cell culture
HEK293 AequoScreen cells (PerkinElmer, Inc., Waltham, MA) stably expressing human GPR39 receptors (HEK293-GPR39 cells) were cultured in DMEM supplemented with 10% FBS and 100 U/ ml penicillin-streptomycin. Tango TM GPCR-bla U2OS cells (Thermo Fisher Scientific Inc., Waltham, MA) stably expressing human GPR39 linked to a TEV protease site and a GAL4-VP16 transcription factor (U2OS-Tango-GPR39 cells) were maintained in McCoy's 5A containing 10% dialyzed FBS, 100 U/ml penicillin G, 100 lg/ml streptomycin sulfate, and 5 mg/ml blasticidin. Passages 10-20 were used for the experiments.
cAMP assay
HEK293-GPR39 cells were plated and cultured in poly-D-lysinecoated, white, 384-well plates (4000 cells/well) in the growth medium overnight at 37°C in the presence of 5% CO 2 . For pretreatment of the cells with GPR39 ligands or vehicle control (DMSO), the culture medium was removed and the cells were stimulated with GPR39 ligands in assay buffer (DMEM containing 10 mM HEPES, pH 7.5, 0.1% fatty acid-free BSA, and 100 U/ml penicillin-s treptomycin) for the indicated time at 37°C. Then, the compound solution was removed and washed twice with PBS containing 0.1% BSA. For measurement of intracellular cAMP, the cells were stimulated with drugs in stimulation buffer [HBSS containing 20 mM HEPES (pH 7.5), 0.1% fatty acid-free BSA, and 1 mM IBMX] for 30 min at 37°C. The intracellular cAMP level was determined by using HTRF cAMP dynamic 2 kits (Cisbio Bioassays, Gif-surYvette, France) according to the manufacturer's instructions. HTRF signals were detected by using EnVision (PerkinElmer, Inc., Waltham, MA).
IP1 assay
Intracellular IP1 accumulation was measured by using HTRF IPOne Tb kit (Cisbio Bioassays, Gif-sur-Yvette, France) according to the manufacturer's instructions. HEK293-GPR39 cells were plated and cultured in poly-D-lysine-coated, white, 384-well plates (7500 cells/well) in the growth medium overnight at 37°C in the presence of 5% CO 2 . The following day, the medium was removed, and the cells were stimulated with test compounds in assay buffer (IP1 stimulation buffer containing 0.1% fatty acid-free BSA) for 1 h at 37°C. Subsequently, IP1-d2 solution and anti-IP1-cryptate Tb conjugate were added, and the plates were incubated for 1 h at room temperature in the dark. HTRF signals were measured by using EnVision (PerkinElmer, Inc., Waltham, MA).
SRF-RE reporter gene assay
HEK293 cells stably expressing SRF-RE-NanoLuc were transfected with human GPR39 by using FuGENE HD (Promega, Madison, WI) and cultured in poly-D-lysine-coated, white, 384-well plates (5000 cells/well) for 2 days at 37°C in the presence of 5% CO 2 . Cells were stimulated with the drugs in assay buffer (DMEM containing 10 mM HEPES, pH 7.5, 0.1% fatty acid-free BSA, and 100 U/ml penicillin-streptomycin) for 3 h at 37°C, and expression of the reporter gene was detected by using a Nano-Glo Luciferase assay kit (Promega, Madison, WI).
b-arrestin recruitment assay
The Tango TM GPCR Assay System (Thermo Fisher Scientific Inc., Waltham, MA) was used to assess b-arrestin recruitment activity. U2OS-Tango-GPR39 cells were plated into black/clear 384-well plates (5000 cells/well) in the growth medium and incubated overnight at 37°C under 5% CO 2 . The medium was removed and 20 ll of assay buffer (McCoy's 5A containing 100 U/ml penicillin G, 100 lg/ml streptomycin sulfate, and 0.1% BSA) was added into each well. Then, the cells were treated with 5 ll of the test compounds dissolved in assay buffer with or without 50 lM ZnCl 2 . After incubation for 5 h at 37°C under 5% CO 2 , 5 ll of the LiveBLAzer FRET B/G substrate (Thermo Fisher Scientific Inc., Waltham, MA) was added. After incubation for 2 h at room temperature, the plates were read on an EnVision reader according to the manufacturer's protocol.
Fluorescence microscopy
HEK293 cells were transiently transfected with human GPR39-AcGFP by using FuGENE HD (Promega, Madison, WI) and seeded in black, clear-bottom, 384-well imaging plates (5000 cells/well) and cultured at 37°C in the presence of 5% CO 2 . On the next day, the culture medium was removed, and the cells were treated with kinase inhibitors or vehicle control (DMSO) for 30 min at 37°C. Then, the cells were stimulated with GPR39 ligands for the indicated time at 37°C, and images were captured by using an IN Cell Analyzer 6000 (GE Healthcare, Tokyo, Japan).
Data analysis
Data were analyzed by using Prism 5 (GraphPad Software Inc., San Diego, CA). The 50% effective concentration values (EC50) in each assay were determined by sigmoidal nonlinear regression fit. Data were analyzed by unpaired Student's t test for comparison between two groups, and by one-way ANOVA with post hoc multiple comparisons for multiple comparisons. P < 0.05 was considered statistically significant.
Results
Discovery of GSB-118 as a GPR39 positive allosteric modulator
We found GSB-118 ( Fig. 1 ) as a novel biased GPR39 PAM through high-throughput screening using cAMP assays. In brief, an approximately 800,000-compound library at 3 lM was screened by cAMP responses in HEK293-hGPR39 cells in the presence of 35 lM ZnCl 2 . False positives were eliminated by counter screens using nontransfected HEK293 cells. Then, the compounds were assessed in a cAMP selectivity assay by using a Gs-coupled bile acid receptor TGR5 in the presence of 3 nM (EC20) of lithocholic acid, which is an endogenous TGR5 ligand, and GPR39-selective compounds were selected. As a result of validation studies using Ca 2+ assays (data not shown), we identified GSB-118 as a biased ligand for GPR39 that potentiated ZnCl 2 -induced cAMP responses without any agonist activity and without any effect on Ca 2+ responses.
Signaling-bias profiles of GPR39-C3 and GSB-118
GSB-118 did not show any agonist activity in cAMP responses (data not shown), as well as GPR39-C3 as reported previously [16] . These results indicate that both GPR39-C3 and GSB-118 allosterically modulate the action of zinc. To identify the signaling-bias profiles, these compounds were assessed in cAMP assays, IP1 assays, SRF-RE reporter gene assays, and b-arrestin recruitment assays (Fig. 2, Table 1 ) in the presence of 20-50 lM zinc (approximately EC20). In these experiments, GPR39-C3 showed potent activity in all assays, which suggested that GPR39-C3 potentiates Gs-, Gq-, G12/13-, and b-arrestinpathways. In contrast, GSB-118 enhanced cAMP production and b-arrestin recruitment, whereas no activation was observed in IP1 accumulation and SRF-RE reporter gene induction, which indicated signal-biased activation (Fig. 2, Table 1 ). An Emax value relative to 300 lM ZnCl 2 was 136 ± 12% in the cAMP response.
Functional desensitization of GPR39 induced by GPR39-C3
To assess the functional desensitization of GPR39, the effect of pretreatment of ZnCl 2 on subsequent activation of the receptor was examined in cAMP assays. As shown in Fig. 3 ZnCl 2 also showed reduction in reactivity to the 2nd challenge of the same compound in a dose-and time-dependent manner ( Fig. 3C and D) . The effect of pretreatment of GPR39-C3 on zinc reactivity was also examined to assess the receptor reactivity to the endogenous ligand. Under the 4-h pretreatment condition, pretreatment of GPR39-C3 at concentrations above 10 nM with 20 lM ZnCl 2 showed significant reductions in the cAMP production induced by 300 lM ZnCl 2 (Fig. 4) . This reduction was bellshaped, possibly due to the sustained effect of GPR39-C3 at high concentrations on cAMP production even after wash-out; 27.6 ± 4.0% of residual cAMP production was observed when cells were pretreated with 1 lM GPR39-C3 with 20 lM ZnCl 2 for 4 h, washed twice, and then incubated with 0.3% DMSO for 30 min before measurement of cAMP levels (data not shown).
Mechanistic analysis of the functional desensitization of GPR39
In many receptors, b-arrestin recruitment induced by phosphorylation of the receptor by GRKs is involved in internalization and downregulation of the receptor [18, 37, 38] . To investigate whether GPR39 desensitization is regulated by b-arrestin recruitment, the effect of Cmpd101, a GRK2 inhibitor [39] , on GPR39-C3-induced functional desensitization was examined. First, the potential of Cmpd101 to inhibit b-arrestin recruitment was assessed in barrestin recruitment TANGO assays. As shown in Fig. 5A, 10 lM Cmpd101 effectively inhibited b-arrestin recruitment induced by GPR39-C3 with 20 lM ZnCl 2 . Although Cmpd101 inhibited barrestin recruitment, Cmpd101 showed no significant effect on 1 lM GPR39-C3-induced desensitization in cAMP assays (Fig. 5B) .
We further addressed the role of downstream signaling of GPR39 by using inhibitors of other downstream molecules. In cAMP assays, Gq-pathway inhibition by 1 lM Gq inhibitor YM-254890 or Gs-pathway inhibition by 100 lM of the adenylyl cyclase inhibitor, SQ22536, or 30 lM of the PKA inhibitor, PKI, had no effects on GPR39 desensitization induced by 10 nM GPR39-C3 with 20 lM ZnCl 2 (Fig. 6) . On the other hand, G12/13-pathway inhibition by 100 lM of the ROCK inhibitor, Y-27632, significantly reversed the reactivity of the cells after 10-nM treatment of GPR39-C3 with 20 lM ZnCl 2 , which suggested involvement of the G12/13/ROCK pathway in functional desensitization of GPR39 (Fig. 6) .
We next examined whether GPR39-C3-induced functional desensitization was mediated by internalization of the receptors. HEK293 cells were transiently transfected with GFP-tagged GPR39 (GPR39-GFP), and localization of the receptor was monitored by fluorescence imaging (Fig. 7) . In these assays, GFP aggregates were observed in some cells regardless of GPR39 stimulation, possibly due to the very high expression of GFP-tagged proteins in such cells. These aggregates may not reflect physiological localization of GPR39 because His-tagged GPR39 has been shown to be localized predominantly on the plasma membrane in HEK293 cells [46] . Under the circumstance, we analyzed the cells in which GPR39-GFP was mainly localized on the cell surface at time 0 and representative images are shown in Fig. 7 . Without stimulation of the receptor, GPR39-GFP was localized on the cell surface (DMSO control). When the cells were stimulated with 300 nM GPR39-C3 with 20 lM ZnCl 2 for 4 h, the receptors were internalized into the cells. These internalizations were partly blocked by 100 lM Y-27632 but not by 10 lM Cmpd101, which suggested that internalization of GPR39 was at least partly regulated by the ROCK pathway and b-arrestin may not be involved in GPR39 internalization.
Effect of pretreatment of biased ligand GSB-118
The results shown in Figs. 5-7 suggest that internalization and desensitization of GPR39 is ROCK dependent. Taken together with the finding that GPR39-C3 stimulates SRF-RE transcription (Fig. 1C) , activation of the G12/13/ROCK pathway via GPR39 may be critical for GPR39-C3-induced GPR39 desensitization. To confirm this, the effect of GSB-118 pretreatment, which had no effect on SRF-RE transcriptional activity (Fig. 1C) , was examined. In the GPR39-GFP localization assay, a large number of the receptors were still on the cell surface after 4-h treatment of 30 lM GSB-118 with 20 lM ZnCl 2 (Fig. 8A) . In the cAMP assay, 4-h pretreatment of GSB-118 with 20 lM ZnCl 2 did not decrease the reactivity of ZnCl 2 . Instead, pretreatment of GSB-118 with 20 lM ZnCl 2 enhanced the reactivity of a 2nd challenge of 300 lM ZnCl 2 in a dose-dependent manner (Fig. 8B) . In addition, pretreatment of GSB-118 also enhanced forskolin-induced cAMP production, which suggested adenylyl cyclase activity potentiation (Fig. 8C ). This effect was not observed in the GPR39-untransfected cells, which indicated that adenylyl cyclace potentiation was dependent on downstream activation of GPR39 (Fig. 8C) . Pretreatment of GPR39-C3 with 20 lM ZnCl 2 also potentiated reactivity of forskolin-induced cAMP production in a dose-dependent manner (data not shown), although this compound decreased zincinduced cAMP production (Fig. 4) . To further address the mechanism of adenylyl cyclase potentiation, the effect of adenylyl cyclase activation by forskolin was examined. When HEK293-hGPR39 cells received 4-h pretreatment of 30 lM forskolin, the reactivity of a Representative graphs from 3 independent experiments performed in triplicate or quadruplicate are shown. 2nd challenge of forskolin was potentiated (176% ± 18%), and this response was blocked by the PKA inhibitor PKI (Fig. 8D) , which suggested that the cAMP/PKA pathway positively regulates adenylyl cyclase activity. Pretreatment of the cells with 10 lM GSB-118 in the presence of 20 lM ZnCl 2 also potentiated forskolin-induced cAMP production (263% ± 16%) and this potentiation was partially inhibited by PKI (212% ± 12%, Fig. 8E ).
Discussion
GPR39 has been thought to be a potential therapeutic target for several diseases, such as type-2 diabetes and depression. Recently, a number of small molecules have been reported to be able to activate a range of signaling pathways, including the Gs, Gq, G12/13, and b-arrestin pathways. However, little is known about the feedback regulation of GPR39 after its activation. Desensitization of GPCRs is a well-known feedback regulatory function that maintains cellular homeostasis, whereas the mechanisms of desensitization are very complicated and dependent on the receptor and ligand.
This is the first report on the functional desensitization of GPR39 by a small molecule ligand, GPR39-C3, in HEK293 cells. GPR39-C3 was first reported as an agonist for GPR39 [15] , but recently this compound was reported to modulate the action of zinc allosterically [16] . GPR39-C3 activated cAMP responses, IP1 accumulation, and SRF-RE reporter gene transcription, which suggested activation of the Gs, Gq, and G12/13 pathways, respectively. GPR39-C3 also potentiated recruitment of b-arrestin. In cAMP assays, this compound decreased the maximum cAMP response of subsequent stimulation in a dose-and time-dependent manner, which revealed the functional desensitization of GPR39. The results of the receptor localization assays suggest that this regulation was attributed to receptor internalization. Interestingly, this feedback regulation was governed by ROCK ( Fig. 9) as confirmed by the experiments using the selective ROCK inhibitor Y-27632. Y-27632 at 100 lM showed little effect on the GPR39-mediated cAMP, IP1, and b-arrestin responses (70 ± 4.4%, 98 ± 2.2%, and 103 ± 13.6% of DMSO-treated control, respectively). To our knowledge, G12/13/ROCK-mediated desensitization of GPCR is the first reported mechanism other than classical b-arrestin-mediated homologous desensitization [37, 40] or PKA-or PKC-mediated heterologous desensitization [18, 29, 41, 42] . In addition, the experiments using the GRK2 inhibitor suggest that b-arrestin, which regulates internalization of many GPCRs, may not be involved in desensitization of GPR39. ROCK proteins (ROCK1 and ROCK2) are serine/threonine kinases with a high degree of homology to other AGC (PKA/PKG/PKC) kinases and are activated by a small GTPase protein RhoA. The RhoA-ROCK pathway mediates signal transduction through a range of cell surface receptors, including G12/13-coupled GPCRs, and has critical roles in cellular activities, such as cytoskeletal dynamics, cell proliferation, and differentiation [43, 44] . Given the G12/13/ ROCK pathway-mediated regulation of GPR39, possible crosstalk between GPR39 and other receptors or molecules can occur depending on cellular activation through the RhoA-ROCK pathway.
Although this study revealed the involvement of ROCK in GPR39 internalization and desensitization, how ROCK works remains unclear. Phosphorylation of GPR39 (direct effect) or another molecule (indirect effect) by ROCK possibly contributes to GPR39 desensitization because Y-27632 inhibits kinase activity of ROCK [45] . There are a number of serine or threonine residues at the intracellular domain of GPR39. Holliday et al. has shown that GPR39 is highly phosphorylated under basal conditions and the phosphorylation levels did not increase by zinc treatment in the 32 P i incorporation assay [46] , whereas the specific phosphorylation site (s) and the kinase involved in GPR39 phosphorylation have not been clarified. Although our results suggest that GRK2 may phosphorylate GPR39 dependent on its activation because GRK2 inhibitor Cmpd101 effectively blocked b-arrestin recruitment to GPR39 (Fig. 5) , the physiological effect of GRK2 on GPR39 is unclear. Further studies are required to understand the detailed mechanism of GPR39 regulation by phosphorylation of the receptor. In addition, further studies on the duration of action of compounds by binding assays and functional assays may help us better understand the desensitization of GPR39 because sustained activation of receptors is relevant to the degree of desensitization in some receptors [47, 48] .
Biased ligands, which preferentially activate one or some of the signaling pathway(s) downstream of the receptors, have recently attracted considerable interest because of their unique pharmacological effects and potential as better drugs or tools [31] [32] [33] . Some research has identified G-protein-biased ligands that had less effect on b-arrestin binding to avoid desensitization of the receptor and drug tolerance [49] . Through high-throughput screening, we identified a novel GPR39 biased allosteric modulator of zinc, GSB-118, that activates Gs and b-arrestin pathways without any effects on Gq and G12/13 responses. Although GSB-118 with zinc elicited full activation of Gs signaling, GSB-118 did not induce desensitization as expected by the results suggesting that GPR39 desensitization depends on the G12/13/ROCK pathway. Taken together with the observation that PKA inhibition did not affect the desensitization of GPR39, our results suggest that GPR39 desensitization is not regulated by PKA downstream of Gs-cAMP responses, unlike some other Gs-coupled receptors, such as b2AR, which has been shown to be phosphorylated and desensitized by PKA [29, 50] . In this study, zinc-dependent allosteric effects of GSB-118 were examined. Additional studies are needed to clarify the probe dependent allosteric effects of GSB-118 on other cations including Ni 2+ , Cr 2+ , Fe 2+ , and Cd 2+ , which can also activate GPR39 [16, 51] .
Interestingly, GSB-118 did not induce internalization and functional desensitization of GPR39 but did potentiate cAMP responses induced by zinc and forskolin probably mediated by activation of adenylyl cyclases. However, potentiation of adenylyl cyclases may not be a universal phenomenon in any other than HEK293 cells because the expression level of each subtype differs depending on the cells, and the subtype(s) of adenylyl cyclases that is/are functionally regulated by PKA remains to be elucidated. To date, 6 subtypes of adenylyl cyclases (AC1, AC3, AC5, AC6, AC7, and AC9) reportedly are expressed in HEK293 cells [52] . Among these subtypes, AC5 and AC6 were shown to be negatively regulated by PKA, and AC1 was not regulated by PKA [53, 54] ; therefore, some other subtypes may be candidates for further testing. Although adenylyl cyclases in HEK293 probably received positive feedback regulation by PKA, as shown in Fig. 8 , GSB-118-induced potentiation of cAMP responses could not be explained only by positive regulation of adenylyl cyclases because the GSB-118-mediated effect was not fully inhibited by the PKA inhibitor, PKI, in contrast to forskolin-mediated responses. In addition, potentiation levels were greater by pretreatment of GSB-118 (263% ± 16%) than by forskolin (176% ± 18%) even though the potential of GSB-118 to induce cAMP production was less than that of forskolin (25% ± 3.3% of 30 lM forskolin). Taken together, cAMP-PKA activation may not be the only reason for potentiation of adenylyl cyclases. These results suggest the existence of unknown mechanisms.
In summary, the desensitization properties of GPR39 related to the functional reactivity and internalization of the receptor were extensively investigated. This research revealed a unique desensitization mechanism regulated by the G12/13/ROCK pathway. We also identified a novel biased ligand, GSB-118, that avoided desensitization by biased signal transduction, which suggests the possibility of designing ligands that stabilize a specific conformational state of GPR39 with unique pharmacological properties. These findings may be helpful for understanding the mechanism of receptor desensitization and development of better drugs targeting GPR39.
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